245 related articles for article (PubMed ID: 15448011)
1. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.
Leenders WP; Küsters B; Verrijp K; Maass C; Wesseling P; Heerschap A; Ruiter D; Ryan A; de Waal R
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6222-30. PubMed ID: 15448011
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment.
Claes A; Gambarota G; Hamans B; van Tellingen O; Wesseling P; Maass C; Heerschap A; Leenders W
Int J Cancer; 2008 May; 122(9):1981-6. PubMed ID: 18081012
[TBL] [Abstract][Full Text] [Related]
3. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
Wedge SR; Ogilvie DJ; Dukes M; Kendrew J; Chester R; Jackson JA; Boffey SJ; Valentine PJ; Curwen JO; Musgrove HL; Graham GA; Hughes GD; Thomas AP; Stokes ES; Curry B; Richmond GH; Wadsworth PF; Bigley AL; Hennequin LF
Cancer Res; 2002 Aug; 62(16):4645-55. PubMed ID: 12183421
[TBL] [Abstract][Full Text] [Related]
4. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
Yano S; Muguruma H; Matsumori Y; Goto H; Nakataki E; Edakuni N; Tomimoto H; Kakiuchi S; Yamamoto A; Uehara H; Ryan A; Sone S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8789-98. PubMed ID: 16361567
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
Ciardiello F; Caputo R; Damiano V; Caputo R; Troiani T; Vitagliano D; Carlomagno F; Veneziani BM; Fontanini G; Bianco AR; Tortora G
Clin Cancer Res; 2003 Apr; 9(4):1546-56. PubMed ID: 12684431
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
Conrad C; Ischenko I; Köhl G; Wiegand U; Guba M; Yezhelyev M; Ryan AJ; Barge A; Geissler EK; Wedge SR; Jauch KW; Bruns CJ
Anticancer Drugs; 2007 Jun; 18(5):569-79. PubMed ID: 17414626
[TBL] [Abstract][Full Text] [Related]
8. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
McCarty MF; Wey J; Stoeltzing O; Liu W; Fan F; Bucana C; Mansfield PF; Ryan AJ; Ellis LM
Mol Cancer Ther; 2004 Sep; 3(9):1041-8. PubMed ID: 15367698
[TBL] [Abstract][Full Text] [Related]
9. Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis.
Küsters B; Kats G; Roodink I; Verrijp K; Wesseling P; Ruiter DJ; de Waal RM; Leenders WP
Oncogene; 2007 Aug; 26(39):5808-15. PubMed ID: 17353901
[TBL] [Abstract][Full Text] [Related]
10. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.
Nicholson B; Gulding K; Conaway M; Wedge SR; Theodorescu D
Clin Cancer Res; 2004 Dec; 10(24):8728-34. PubMed ID: 15623658
[TBL] [Abstract][Full Text] [Related]
11. Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.
Damiano V; Melisi D; Bianco C; Raben D; Caputo R; Fontanini G; Bianco R; Ryan A; Bianco AR; De Placido S; Ciardiello F; Tortora G
Clin Cancer Res; 2005 Aug; 11(15):5639-44. PubMed ID: 16061883
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor-A determines detectability of experimental melanoma brain metastasis in GD-DTPA-enhanced MRI.
Leenders W; Küsters B; Pikkemaat J; Wesseling P; Ruiter D; Heerschap A; Barentsz J; de Waal RM
Int J Cancer; 2003 Jul; 105(4):437-43. PubMed ID: 12712432
[TBL] [Abstract][Full Text] [Related]
13. The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma.
Drevs J; Konerding MA; Wolloscheck T; Wedge SR; Ryan AJ; Ogilvie DJ; Esser N
Angiogenesis; 2004; 7(4):347-54. PubMed ID: 15886878
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.
Tuccillo C; Romano M; Troiani T; Martinelli E; Morgillo F; De Vita F; Bianco R; Fontanini G; Bianco RA; Tortora G; Ciardiello F
Clin Cancer Res; 2005 Feb; 11(3):1268-76. PubMed ID: 15709198
[TBL] [Abstract][Full Text] [Related]
15. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.
Matsumori Y; Yano S; Goto H; Nakataki E; Wedge SR; Ryan AJ; Sone S
Oncol Res; 2006; 16(1):15-26. PubMed ID: 16783964
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.
Beaudry P; Force J; Naumov GN; Wang A; Baker CH; Ryan A; Soker S; Johnson BE; Folkman J; Heymach JV
Clin Cancer Res; 2005 May; 11(9):3514-22. PubMed ID: 15867254
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis.
Küsters B; Leenders WP; Wesseling P; Smits D; Verrijp K; Ruiter DJ; Peters JP; van Der Kogel AJ; de Waal RM
Cancer Res; 2002 Jan; 62(2):341-5. PubMed ID: 11809675
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.
Wu W; Onn A; Isobe T; Itasaka S; Langley RR; Shitani T; Shibuya K; Komaki R; Ryan AJ; Fidler IJ; Herbst RS; O'Reilly MS
Mol Cancer Ther; 2007 Feb; 6(2):471-83. PubMed ID: 17308046
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI.
Boult JKR; Box G; Vinci M; Perryman L; Eccles SA; Jones C; Robinson SP
Neoplasia; 2017 Sep; 19(9):684-694. PubMed ID: 28780387
[TBL] [Abstract][Full Text] [Related]
20. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.
Rich JN; Sathornsumetee S; Keir ST; Kieran MW; Laforme A; Kaipainen A; McLendon RE; Graner MW; Rasheed BK; Wang L; Reardon DA; Ryan AJ; Wheeler C; Dimery I; Bigner DD; Friedman HS
Clin Cancer Res; 2005 Nov; 11(22):8145-57. PubMed ID: 16299247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
